A Phase 2 interventional study of rilzabrutinib and placebo in Chronic Spontaneous Urticaria, sponsored by Sanofi. Completed at 128 sites in 13 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Chronic Urticaria with a site in Poland — 4 open to participants now, 9 under way, 6 of them phase 3. Chronic Urticaria · Poland.
Among the 28 studies in Chronic Urticaria with a site in Poland, this one is the 19th largest by enrollment, is one of 3 that started in 2021, is one of 14 in phase 2, and was the 14th registered.
197 studies on the registry are indexed under Chronic Urticaria; 49 are open to participants now.
Browse Chronic Urticaria studies →4 of the 28 studies in Chronic Urticaria with a site in Poland are open now. Recruiting first, the newest first:
Yuhan Corporation · Sites in Poland, Bulgaria, China and 1 more country
Ages 18–75
Pfizer · Sites in Poland, United States, Bulgaria and 7 more countries
Ages 18+
Novartis Pharmaceuticals · Sites in Poland, United States, France and 2 more countries
Ages 18+
Celldex Therapeutics · Sites in Poland, United States, Argentina and 27 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 270 across the 28 interventional studies. Of the 19 that completed or were terminated, 17 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 28 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,559 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 5 studies filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
3 of the studies in Chronic Urticaria with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
| NCT07415551Yuhan CorporationPhase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines | 2027-06-19 |
| NCT06865651Novartis PharmaceuticalsStudy of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria | 2027-08-23 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Chronic Urticaria with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The first phase of this study will be a parallel, 12-week treatment, Phase 2, double-blind, 4 arm study to assess the safety and effectiveness of 3 oral doses of SAR444671 (rilzabrutinib), i.e. dose A, B and C, compared with placebo for decreasing the frequency and severity of itch and urticaria in male and female participants aged 18 years inclusive or older with CSU.
After completion of the double-blind phase of the study, participants will be given the option of enrolling in the 40-week open label extension (OLE) phase of the study. Participants will receive open-label rilzabrutinib at dose B or dose C (the dose may be modified based on the 12-week safety and efficacy data). Due to the fact that some participants may be receiving rilzabrutinib for the first time, all participants will be monitored at Week 14, Week 16, Week 20, and Week 24. Afterwards, participants will be monitored at Week 36 and Week 52.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dose A
Drug: rilzabrutinib
dose B
Drug: rilzabrutinib
dose C
Drug: rilzabrutinib
Matching placebo
Drug: placebo
Tablet, oral use
Also known as: PRN1008/SAR444671
Tablet, oral use
Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12
The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.
Time frame: Baseline and Week 12
Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12
The ISS represents the itch severity on a scale and was recorded by the participant in their e-diary ranging from 0 (None) to 3 (intense). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.
Time frame: Baseline and Week 12
Change From Baseline in Weekly Urticaria Activity Score at Week 4
The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Baseline is defined as the sum of the 7 measurements obtained within the 7 days prior to randomization.
Time frame: Baseline and Week 4
Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12
The HSS7 represents hive severity score on a scale recorded on e-diary ranging from 0 (None) to 3 (more than 50 hives). A weekly score (HSS7) was sum of the average daily scores of the previous 7 days. The possible range of the weekly score was 0-21 (highest hives activity). Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.
Time frame: Baseline and Week 12
Percentage of Participants With Weekly Urticaria Activity Score Less Than or Equal to (≤)6 at Week 12
The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Here, a score ≤6 indicates well-controlled disease.
Time frame: At Week 12
Percentage of Participants With Weekly Urticaria Activity Score Equal to 0 at Week 12
The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Here, score 0 indicates an absence of both itches and hives and a complete resolution of chronic spontaneous urticaria (CSU) symptoms.
Time frame: At Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (TESAEs), Treatment-Emergent Adverse Events of Special Interest (AESIs), and Withdrawals Due to Treatment-Emergent Adverse Events
Adverse event (AE): any untoward medical occurrence in participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs: AEs that developed or worsened or became serious during treatment-emergent period, defined as time from first administration of study treatment (on Day 1) to last administration of study treatment + 7 days. SAE: any AE that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. An AESI was an TEAE (serious or nonserious) of scientific and medical concern specific to Sponsor's product or program.
Time frame: From first dose of study treatment (Day 1) up to last dose of study treatment + 7 days, approximately 13 weeks for DB period and approximately 41 weeks for OLE period
Plasma Concentration of Rilzabrutinib
Plasma samples were collected at specified timepoints for evaluation of rilzabrutinib pharmacokinetic (PK) concentrations.
Time frame: Pre-dose and 2 hours post-dose at Day 1 and Week 4; pre-dose at Week 12 (DB period); pre-dose and 2 hours post-dose at Week 16; pre-dose at Weeks 20, 24 and 52 (OLE period)
The study was conducted at 59 active centers in 13 countries. A total of 240 participants were screened between 24 November 2021 and 28 February 2023, of which 80 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.
| Milestone | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | OLE Period: Rilzabrutinib 400 mg BID | OLE Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|---|---|
| Started | 40 | 38 | 41 | 41 | 0 | 0 |
| Completed | 37 | 34 | 35 | 36 | 0 | 0 |
| Not completed | 3 | 4 | 6 | 5 | 0 | 0 |
| Withdrew: Other | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 3 | 2 | 4 | 4 | 0 | 0 |
| Withdrew: Poor compliance to protocol | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 0 | 0 |
| Milestone | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | OLE Period: Rilzabrutinib 400 mg BID | OLE Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 9 | 128 |
| Completed | 0 | 0 | 0 | 0 | 6 | 98 |
| Not completed | 0 | 0 | 0 | 0 | 3 | 30 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 17 |
| Withdrew: Poor compliance to protocol | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 7 |
The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.
| score on a scale | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| Change From Baseline in Weekly Urticaria Activity Score (UAS7) at Week 12 | -10.14 ± 2.05 | -9.74 ± 2.00 | -14.24 ± 2.06 | -16.89 ± 2.04 |
The ISS represents the itch severity on a scale and was recorded by the participant in their e-diary ranging from 0 (None) to 3 (intense). The ISS7 is the sum of ISS for the previous 7 days. The ISS7 represents itch severity on a scale ranging from 0 (minimum) to 21 (maximum). Higher scores indicate greater intensity of itch. Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.
| score on a scale | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| Change From Baseline in Weekly Itch Severity Score (ISS7) at Week 12 | -5.77 ± 1.05 | -5.19 ± 1.02 | -7.73 ± 1.06 | -9.21 ± 1.05 |
The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Baseline is defined as the sum of the 7 measurements obtained within the 7 days prior to randomization.
| score on a scale | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| Change From Baseline in Weekly Urticaria Activity Score at Week 4 | -7.06 ± 1.72 | -9.14 ± 1.66 | -12.89 ± 1.73 | -13.66 ± 1.72 |
The HSS7 represents hive severity score on a scale recorded on e-diary ranging from 0 (None) to 3 (more than 50 hives). A weekly score (HSS7) was sum of the average daily scores of the previous 7 days. The possible range of the weekly score was 0-21 (highest hives activity). Baseline is defined as the sum of the 7 days measurements obtained on and prior to the target visit day.
| score on a scale | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| Change From Baseline in Weekly Hives Severity Score (HSS7) at Week 12 | -4.40 ± 1.06 | -4.49 ± 1.04 | -6.52 ± 1.07 | -7.64 ± 1.06 |
The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Here, a score ≤6 indicates well-controlled disease.
| percentage of participants | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| Percentage of Participants With Weekly Urticaria Activity Score Less Than or Equal to (≤)6 at Week 12 | 11.1 | 5.4 | 20.0 | 34.3 |
The UAS7 score is a composite score containing both the hive severity score (HSS, ranging from 0 = None to 3 = more than 50 hives) and the itch severity score (ISS, ranging from 0 = None to 3 = intense). The daily UAS scores ranged from 0 to 6 points per day. Daily UAS scores were summed over a 7-day period to create the UAS7, ranging from 0 to 42, and are composed of the HSS7 and ISS7 components. A higher score indicates worse disease. Here, score 0 indicates an absence of both itches and hives and a complete resolution of chronic spontaneous urticaria (CSU) symptoms.
| percentage of participants | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|
| Percentage of Participants With Weekly Urticaria Activity Score Equal to 0 at Week 12 | 11.1 | 2.7 | 14.3 | 20.0 |
Adverse event (AE): any untoward medical occurrence in participant or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. TEAEs: AEs that developed or worsened or became serious during treatment-emergent period, defined as time from first administration of study treatment (on Day 1) to last administration of study treatment + 7 days. SAE: any AE that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. An AESI was an TEAE (serious or nonserious) of scientific and medical concern specific to Sponsor's product or program.
| Participants | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | OLE Period: Rilzabrutinib 400 mg BID | OLE Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|---|---|
| TEAEs | 23 | 23 | 30 | 31 | 7 | 89 |
| TESAEs | 1 | 0 | 0 | 2 | 1 | 4 |
| Treatment-Emergent AESIs | 2 | 4 | 4 | 3 | 4 | 5 |
| Withdrawals due to TEAEs | 0 | 0 | 1 | 1 | 0 | 6 |
Plasma samples were collected at specified timepoints for evaluation of rilzabrutinib pharmacokinetic (PK) concentrations.
| nanogram per milliliter (ng/mL) | DB Period: Rilzabrutinib 400 mg QPM | DB Period: Rilzabrutinib 400 mg BID | DB Period: Rilzabrutinib 400 mg TID | OLE Period: Rilzabrutinib 400 mg BID | OLE Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|---|
| Day 1: pre-dose | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | — | — |
| Day 1: 2 hours post-dose | 1.43 ± 8.49 | 133.77 ± 113.67 | 181.16 ± 139.41 | — | — |
| Week 4: pre-dose | 13.83 ± 26.40 | 26.46 ± 62.95 | 27.73 ± 67.72 | — | — |
| Week 4: 2 hours post-dose | 5.63 ± 9.60 | 186.40 ± 122.19 | 266.13 ± 232.15 | — | — |
| Week 12: pre-dose | 5.68 ± 7.79 | 11.83 ± 18.80 | 25.18 ± 76.01 | — | — |
| Week 16: pre-dose | — | — | — | 2.49 ± 1.66 | 24.90 ± 44.17 |
| Week 16: 2 hours post-dose | — | — | — | 153.22 ± 145.99 | 236.47 ± 204.47 |
| Week 20: pre-dose | — | — | — | 1.97 ± 0.82 | 34.85 ± 83.79 |
| Week 24: pre-dose | — | — | — | 3.31 ± 1.40 | 16.01 ± 29.32 |
| Week 52: pre-dose | — | — | — | 3.51 ± 1.96 | 20.77 ± 39.33 |
Collected over Adverse events data were collected from first dose of study treatment (Day 1) up to last dose of study treatment + 7 days approximately 13 weeks for DB period and approximately 41 weeks for OLE period. All-cause mortality (death) was assessed from the signing of the ICF up to approximately 125 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DB Period: Placebo TID | 0/40 (0%) | 1/40 (2.5%) | 14/40 (35%) |
| DB Period: Rilzabrutinib 400 mg QPM + Placebo | 0/38 (0%) | 0/38 (0%) | 20/38 (52.6%) |
| DB Period: Rilzabrutinib 400 mg BID + Placebo | 0/41 (0%) | 0/41 (0%) | 26/41 (63.4%) |
| DB Period: Rilzabrutinib 400 mg TID | 0/41 (0%) | 2/41 (4.9%) | 25/41 (61%) |
| OLE Period: Rilzabrutinib 400 mg BID | 0/9 (0%) | 1/9 (11.1%) | 7/9 (77.8%) |
| OLE Period: Rilzabrutinib 400 mg TID | 0/128 (0%) | 4/128 (3.1%) | 59/128 (46.1%) |
| Event | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | OLE Period: Rilzabrutinib 400 mg BID | OLE Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|---|---|
| Joint DislocationInjury, poisoning and procedural complications | 0/40 | 0/38 | 0/41 | 0/41 | 1/9 | 0/128 |
| Ligament RuptureInjury, poisoning and procedural complications | 0/40 | 0/38 | 0/41 | 0/41 | 1/9 | 0/128 |
| Peritonsillar AbscessInfections and infestations | 1/40 | 0/38 | 0/41 | 0/41 | 0/9 | 0/128 |
| UrticariaSkin and subcutaneous tissue disorders | 0/40 | 0/38 | 0/41 | 1/41 | 0/9 | 1/128 |
| Iatrogenic InjuryInjury, poisoning and procedural complications | 0/40 | 0/38 | 0/41 | 1/41 | 0/9 | 0/128 |
| Viral Upper Respiratory Tract InfectionInfections and infestations | 0/40 | 0/38 | 0/41 | 0/41 | 0/9 | 1/128 |
| Anaphylactic ShockImmune system disorders | 0/40 | 0/38 | 0/41 | 0/41 | 0/9 | 1/128 |
| Vogt-Koyanagi-Harada DiseaseEye disorders | 0/40 | 0/38 | 0/41 | 0/41 | 0/9 | 1/128 |
| Event | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | OLE Period: Rilzabrutinib 400 mg BID | OLE Period: Rilzabrutinib 400 mg TID |
|---|---|---|---|---|---|---|
| Covid-19Infections and infestations | 2/40 | 2/38 | 4/41 | 2/41 | 3/9 | 2/128 |
| NasopharyngitisInfections and infestations | 2/40 | 1/38 | 1/41 | 2/41 | 3/9 | 9/128 |
| DiarrhoeaGastrointestinal disorders | 6/40 | 3/38 | 12/41 | 12/41 | 1/9 | 19/128 |
| NauseaGastrointestinal disorders | 2/40 | 5/38 | 7/41 | 8/41 | 1/9 | 17/128 |
| HeadacheNervous system disorders | 0/40 | 2/38 | 6/41 | 4/41 | 0/9 | 7/128 |
| Abdominal PainGastrointestinal disorders | 2/40 | 1/38 | 5/41 | 0/41 | 1/9 | 5/128 |
| SinusitisInfections and infestations | 0/40 | 0/38 | 1/41 | 0/41 | 1/9 | 1/128 |
| Vulvovaginal CandidiasisInfections and infestations | 0/40 | 0/38 | 0/41 | 0/41 | 1/9 | 1/128 |
| LymphopeniaBlood and lymphatic system disorders | 0/40 | 0/38 | 0/41 | 0/41 | 1/9 | 0/128 |
| Decreased AppetiteMetabolism and nutrition disorders | 0/40 | 0/38 | 0/41 | 1/41 | 1/9 | 0/128 |
The randomized population consisted of all participants from screened population (who signed the informed consent form \[ICF\]) and had been allocated to a randomized study treatment by interactive response technology (IRT), regardless of whether the study treatment was received.
| Age, Continuous(years) | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | Total |
|---|---|---|---|---|---|
| Mean | 40.2 ± 14.0 | 42.1 ± 12.7 | 45.5 ± 13.4 | 48.5 ± 12.2 | 44.1 ± 13.4 |
| Sex: Female, Male(Participants) | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | Total |
|---|---|---|---|---|---|
| Female | 26 | 28 | 25 | 33 | 112 |
| Male | 14 | 10 | 16 | 8 | 48 |
| Race (NIH/OMB)(Participants) | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 1 |
| Asian | 9 | 11 | 8 | 10 | 38 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 31 | 27 | 33 | 30 | 121 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Weekly Urticaria Activity Score (UAS7)(score on a scale) | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | Total |
|---|---|---|---|---|---|
| Mean | 30.0 ± 8.6 | 31.4 ± 7.3 | 30.2 ± 7.2 | 29.9 ± 8.6 | 30.3 ± 7.9 |
| Weekly Itch Severity Score (ISS7)(score on a scale) | DB Period: Placebo TID | DB Period: Rilzabrutinib 400 mg QPM + Placebo | DB Period: Rilzabrutinib 400 mg BID + Placebo | DB Period: Rilzabrutinib 400 mg TID | Total |
|---|---|---|---|---|---|
| Mean | 15.6 ± 4.2 | 16.5 ± 3.5 | 15.8 ± 3.7 | 15.9 ± 4.4 | 15.9 ± 4.0 |
Showing the first 100 of 128 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Nov 2021 to primary completion in Jul 2023, 19 months.
Results were first posted in Aug 2026, 3 years after primary completion. A results delay was requested in Jul 2024.
Of 31 phase 2 interventional studies under Chronic Urticaria, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 19 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilzabrutinib